
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline can... Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.23 | -10.3139013453 | 2.23 | 2.31 | 1.95 | 9408238 | 2.09597476 | CS |
4 | 0.3 | 17.6470588235 | 1.7 | 2.47 | 1.67 | 11838529 | 2.02696317 | CS |
12 | -1.59 | -44.2896935933 | 3.59 | 3.73 | 1.6385 | 17101042 | 2.2612592 | CS |
26 | -5.17 | -72.1059972106 | 7.17 | 8.15 | 1.6385 | 13095168 | 3.38811317 | CS |
52 | -5.82 | -74.4245524297 | 7.82 | 12.505 | 1.6385 | 9702049 | 5.41897799 | CS |
156 | -6.87 | -77.4520856821 | 8.87 | 18.33 | 1.6385 | 6972029 | 7.21084362 | CS |
260 | -28.13 | -93.3620975772 | 30.13 | 54.2081 | 1.6385 | 5063556 | 9.89191924 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.